Rule 3.8A

Appendix 3E

Daily share buy-back notice (except minimum holding buy-back and selective buy-back)

Information and documents given to ASX become ASX's property and may be made public.

	e of entity		ABN/ARSN			
Sign	ma Pharmaceuticals Limited		15 088 417 403			
We	(the entity) give ASX the following	information.				
Info	ormation about buy-back					
1	Type of buy-back	On-market buy-back				
2	Date Appendix 3C was given to ASX	13 September 2012 (Associated Appendix 3D dated 18 November 2015)				
	Total of all shares/units bought back, or in relation to which acceptances have been received, before, and on, previous day					
		Before previous day	Previous day			
3	Number of shares/units bought back or if buy-back is an equal access scheme, in relation to which acceptances have been received	Before previous day 110,671,420	Previous day			
3	back or if buy-back is an equal access scheme, in relation to which acceptances have been	-	,			

Before previous day			Previous day			
Highest \$0.8525	price	paid	d:	Highest \$0.8500	price	paid

5 If buy-back is an on-market buy-

Highest \$0.8525	price	paid:	Highest price paid: \$0.8500		
Lawast			Lowest price paid: \$0.8400		
\$0.5600	price	paid:	Highest price allowed under rule 7.33: \$0.8625		

How many shares/units may still be bought back?

6	If the company/trust has disclosed
	an intention to buy back a
	maximum number of shares/units
	- the remaining number of
	shares/units to be bought back

7,858,932			

Compliance statement

- 1. The company is in compliance with all Corporations Act requirements relevant to this buy-back.
- 2. There is no information that the listing rules require to be disclosed that has not already been disclosed, or is not contained in, or attached to, this form.

or, for trusts only:

- 1. The trust is in compliance with all requirements of the Corporations Act as modified by Class Order 07/422, and of the trust's constitution, relevant to this buy-back.
- 2. There is no information that the listing rules require to be disclosed that has not already been disclosed, or is not contained in, or attached to, this form.

Sign here:

Date: 26 November 2015

(Director/Company secretary)

Print name: JEFF SELLS